2nd Annual Virtual Tumor Board®: Navigating Novel Therapeutic Approaches for the Management of SCLC Across Lines of Care

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from G1 Therapeutics, Inc. and Jazz Pharmaceuticals, Inc.

 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine how novel approaches for care have changed treatment paradigms for patients with SCLC
• Apply clinical trial evidence to optimize the efficacy and safety of SCLC treatment approaches in multiple lines of care and a variety of real-world case-based scenarios
• Discuss emerging strategies for the treatment of extensive- and limited-stage SCLC in the context of highly anticipated ongoing trials in the field of lung cancer management.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.
 

Chair

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Medical Oncology
Professor of Pharmacology
Director, Center for Thoracic Cancers
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital

Associate Cancer Center Director
Translational Science
Yale Cancer Center, Yale School of Medicine
New Haven, CT

Disclosures: Grant research support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company; Consultant: AbbVie, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Foundation Medicine, Genentech/Hoffmann-La Roche, Genmab, Gilead Sciences, Halozyme Therapeutics, Heat Biologics, HiberCell, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson & Johnson, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar Therapeutics, Neon Therapeutics, NextCure, Novartis Pharmaceuticals Corporation, Ocean Biomedical, Oncternal Therapeutics, Pfizer, Refactor Health, Ribon Therapeutics, Sanofi, Seattle Genetics, Shire Pharmaceuticals, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda Pharmaceutical Company, Tesaro, Tocagen, Ventana Medical Systems, WindMIL Therapeutics, Xencor; Other: Board Member (nonexecutive/ independent): Immunocore Holdings Ltd, Junshi Biosciences.

Faculty

Alberto Chiappori, MD
Senior Member
Department of Thoracic Oncology
Moffitt Cancer Center
Tampa, FL

Disclosures: Grant/Research Support: Bristol Myers Squibb AstraZeneca, Novartis; Consultant: AstraZeneca; Jazz, Pfizer; Speakers’ Bureau: Takeda, Amgen, Genentech, Blueprint Medicines, Johnson & Johnson; Stock/Shareholder: Merck.

 

W. Victoria Lai, MD
Assistant Professor
Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures:  W. Victoria Lai, MD, has no relevant financial relationships with ineligible companies.
 

Jared Weiss, MD
Section Chief of Thoracic and Head/Neck Oncology
Associate Professor of Medicine
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Disclosures: Grant/Research Support: Mirati, Sumitomo Dainippon Pharma, Boehringer Ingelheim, PDS Biotech, Merck, AZ, Amgen, CareFusion, G1 Therapeutics, Immunicum, Lilly; Consultant: AZ, EMD Serono, Genentech, G1 Therapeutics, Jounce Therapeutics, AbbVie, Nanobiotix, Azitra, Lilly, Blueprint Medicines, Pfizer, Saatchi, Jazz, BI, Regeneron, Genmab, BeiGene; Stock/Shareholder: Achilles Therapeutics, Nektar Therapeutics, Vesselon, Nuvalent, Lyell Immunopharma, Inc.
 

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.